Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 20/20 | 0.44 |
| ▸ | PPARG | P37231 | 10/20 | 0.43 |
| ▸ | PPARD | Q03181 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13792902 | 1.00 | PPARA (0.44) | PPARAPPARGPPARD | |
| SCHEMBL13805064 | 0.97 | PPARA (0.44) | PPARAPPARGPPARD | |
| SCHEMBL13804956 | 0.95 | PPARA (0.46) | PPARAPPARGPPARD | |
| SCHEMBL3996646 | 0.95 | PPARA (0.46) | PPARAPPARGPPARD | |
| SCHEMBL13792746 | 0.95 | PPARA (0.46) | PPARAPPARGPPARD | |
| SCHEMBL3990660 | 0.94 | PPARA (0.45) | PPARAPPARGPPARD | |
| SCHEMBL3998107 | 0.94 | PPARA (0.42) | PPARAPPARGPPARD | |
| SCHEMBL3991134 | 0.91 | PPARA (0.41) | PPARAPPARGPPARD | |
| SCHEMBL3990841 | 0.91 | PPARA (0.40) | PPARAPPARGPPARD | |
| SCHEMBL3990928 | 0.90 | PPARG (0.41) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544812-B2 | For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050020652-A1 | Peroxisome proliferator activated receptor agonists | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| EP-1453811-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003048130-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020652-A1 | Peroxisome proliferator activated receptor agonists | PPARA, PPARD, PPARG | PPARA 1/4885PPARG 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.